home / stock / rytm / rytm news

RYTM News and Press, Rhythm Pharmaceuticals Inc. From 02/17/22

Stock Information
Company Name: Rhythm Pharmaceuticals Inc.
Stock Symbol: RYTM
Market: NASDAQ
Website: rhythmtx.com
Menu
RYTM RYTM Quote RYTM Short RYTM News RYTM Articles RYTM Message Board
Get RYTM Alerts

News, Short Squeeze, Breakout and More Instantly...
RYTM - Aridis, Rhythm top healthcare gainers; 10x Genomics, iSpecimen lead losers pack

Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
RYTM - FFIE, RYTM and TNET among pre market gainers

Marin Software (NASDAQ:MRIN) +25% on TikTok integration in platform. DoorDash (NYSE:DASH) +24% on Q4 results. Global-e Online (NASDAQ:GLBE) +15% on Q4 results. TriNet (NYSE:TNET) +9% commences a modified dutch auction tender offer to repurchase up to $300M o...

RYTM - Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

-- Patients with BBS achieved deepened and sustained weight loss at 24 months on setmelanotide therapy -- -- Company to provide update on U.S. BBS commercial readiness during virtual event today at 4 p.m. ET -- BOSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica...

RYTM - Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts -- -- Prescription Drug User Fee Act (PDUFA) goal date for setmelanotide for patients w...
RYTM - Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity -- -- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes -- -- First patient also dosed...

RYTM - Rhythm Pharma inks licensing deal for development of Imcivree in China

Rhythm Pharmaceuticals (NASDAQ:RYTM) announces an exclusive licensing agreement with and China-based RareStone LTD, for the development and commercialization of Imcivree (setmelanotide) in China, including mainland China, Hong Kong and Macau. According to the terms of the agreement, RareStone...

RYTM - Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau -- -- Rhythm to receive $12 million upfront in cash and equity, up to $63....
RYTM - Rhythm Pharma granted FDA priority review for label expansion of weight loss drug

Rhythm Pharmaceuticals (NASDAQ:RYTM) has added ~5.4% in the pre-market after announcing that the FDA accepted the company’s supplemental New Drug Application ((sNDA)) for IMCIVREE (setmelanotide) for Bardet-Biedl syndrome (BBS) or Alström syndrome. The regulator has...

RYTM - Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) h...

RYTM - Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Exe...
Previous 10 Next 10